AEMD Aethlon Medical, Inc.
USHealthcareAs of 2026-07-10 16:00
Why AEMD matters now
Aethlon Medical, Inc. (AEMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.71 with +1.87% on the session and $539.0K in market capitalization; recent performance reads 1-month -7.80% and YTD -31.77%.
The latest financial table shown here is Q4 2026, with revenue of $0.00, net income of $-1.9M, and EPS of $-1.20. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -486175453.9%.
The latest indexable market news headline is "Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Gikakis Nicolas filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.61
P/S
0.00
EV/EBITDA
0.49
DCF Value
$6.44
FCF Yield
-486175453.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-137.7%
ROA
-112.9%
ROIC
-139.6%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2026 | $0.00 | $-1.9M | $-1.20 |
| FY 2026 | $0.00 | $-7.2M | $-10.61 |
| Q3 2026 | $0.00 | $-2.0M | $-2.45 |
| Q2 2026 | $0.00 | $-1.5M | $-3.74 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.32
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.